[go: up one dir, main page]

FR22C1049I1 - CONDENSED HETEROCYCLIC DERIVATIVE SALT AND CRYSTALS THEREOF - Google Patents

CONDENSED HETEROCYCLIC DERIVATIVE SALT AND CRYSTALS THEREOF

Info

Publication number
FR22C1049I1
FR22C1049I1 FR22C1049C FR22C1049C FR22C1049I1 FR 22C1049 I1 FR22C1049 I1 FR 22C1049I1 FR 22C1049 C FR22C1049 C FR 22C1049C FR 22C1049 C FR22C1049 C FR 22C1049C FR 22C1049 I1 FR22C1049 I1 FR 22C1049I1
Authority
FR
France
Prior art keywords
crystals
condensed heterocyclic
heterocyclic derivative
derivative salt
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1049C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of FR22C1049I1 publication Critical patent/FR22C1049I1/en
Application granted granted Critical
Publication of FR22C1049I2 publication Critical patent/FR22C1049I2/en
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62Quaternary ammonium compounds
    • C07C211/63Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR22C1049C 2010-02-10 2022-09-26 CONDENSED HETEROCYCLIC DERIVATIVE SALT AND CRYSTAL THEREOF Active FR22C1049I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010027806 2010-02-10
PCT/JP2011/052719 WO2011099507A1 (en) 2010-02-10 2011-02-09 Salt of fused heterocyclic derivative and crystal thereof

Publications (2)

Publication Number Publication Date
FR22C1049I1 true FR22C1049I1 (en) 2022-12-09
FR22C1049I2 FR22C1049I2 (en) 2023-11-24

Family

ID=44367777

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1049C Active FR22C1049I2 (en) 2010-02-10 2022-09-26 CONDENSED HETEROCYCLIC DERIVATIVE SALT AND CRYSTAL THEREOF

Country Status (17)

Country Link
US (5) US9169266B2 (en)
EP (1) EP2535342B1 (en)
JP (1) JP5337261B2 (en)
KR (1) KR101631143B1 (en)
CN (1) CN102753557B (en)
AU (1) AU2011215250B2 (en)
BR (1) BR112012020110B1 (en)
CA (1) CA2788533C (en)
ES (1) ES2502740T3 (en)
FR (1) FR22C1049I2 (en)
IL (1) IL221325A (en)
MX (1) MX2012009323A (en)
NZ (1) NZ601684A (en)
RU (1) RU2557237C2 (en)
SG (1) SG183243A1 (en)
TW (1) TWI555751B (en)
WO (1) WO2011099507A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014042176A1 (en) * 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 Method for producing fused-heterocyclic derivative, and production intermediate thereof
CN109562112A (en) * 2016-08-08 2019-04-02 橘生药品工业株式会社 Methods and dosages for endometriosis therapeutics
CA3066190A1 (en) 2017-06-05 2018-12-13 ObsEva S.A. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
FI3634419T3 (en) * 2017-06-05 2025-05-02 Kissei Pharmaceutical Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss
AU2019373349B2 (en) 2018-10-29 2025-01-09 Kissei Pharmaceutical Co., Ltd. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
SG11202104053TA (en) 2018-11-07 2021-05-28 ObsEva SA Compositions and methods for the treatment of estrogen-dependent disorders
CA3150089A1 (en) 2019-08-08 2021-02-11 ObsEva S.A. Gnrh antagonists for the treatment of estrogen-dependent disorders
CA3148939A1 (en) 2019-08-08 2021-02-11 ObsEva S.A. Compositions and methods for the treatment of estrogen-dependent disorders
CN115232144B (en) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof
CN115636839B (en) * 2021-07-19 2025-11-14 上海科胜药物研发有限公司 A fused heterocyclic derivative crystal form C and its preparation method
IL314697A (en) 2022-02-04 2024-10-01 Kissei Pharmaceutical Oral solid preparation
CN119836428A (en) * 2022-09-02 2025-04-15 瑞科斯医药科技有限公司 Benfotiamine choline salt

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56108787A (en) * 1980-01-31 1981-08-28 Sato Yakugaku Kenkyusho:Kk Camptothecin coline salt and its preparation
US4663348A (en) 1985-07-02 1987-05-05 Warner-Lambert Co. Furosemide salts and pharmaceutical preparations thereof
DE3830932A1 (en) * 1988-09-12 1990-03-15 Diamalt Ag 2-HYDROXY-N, N, N-TRIMETHYL ETHANAMINIUM SALTS OF 5SS-CHOLAN-24-ACID DERIVATIVES
DK1939204T6 (en) 2005-10-19 2022-09-05 Kissei Pharmaceutical Condensed heterocyclic derivative, medicinal composition containing same and medicinal use thereof
CN101331134B (en) * 2005-10-19 2012-11-28 橘生药品工业株式会社 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
GB0603522D0 (en) * 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition
RU2345996C1 (en) * 2007-07-17 2009-02-10 Андрей Александрович Иващенко Annelated azaheterocyclic amides, which include pyrimidine fragment, method of obtaining and their application

Also Published As

Publication number Publication date
RU2557237C2 (en) 2015-07-20
US9737539B2 (en) 2017-08-22
US20160082010A1 (en) 2016-03-24
WO2011099507A1 (en) 2011-08-18
CN102753557B (en) 2015-10-14
TW201144319A (en) 2011-12-16
CN102753557A (en) 2012-10-24
IL221325A0 (en) 2012-10-31
EP2535342A4 (en) 2013-07-10
BR112012020110A2 (en) 2018-03-20
IL221325A (en) 2016-09-29
JPWO2011099507A1 (en) 2013-06-13
US10576084B2 (en) 2020-03-03
US20200390768A1 (en) 2020-12-17
US9169266B2 (en) 2015-10-27
FR22C1049I2 (en) 2023-11-24
CA2788533C (en) 2018-03-06
JP5337261B2 (en) 2013-11-06
KR20130002984A (en) 2013-01-08
MX2012009323A (en) 2012-11-21
US20190134038A1 (en) 2019-05-09
US10016433B2 (en) 2018-07-10
KR101631143B1 (en) 2016-06-17
US20170319588A1 (en) 2017-11-09
NZ601684A (en) 2013-08-30
US20130059867A1 (en) 2013-03-07
CA2788533A1 (en) 2011-08-18
EP2535342B1 (en) 2014-08-06
AU2011215250B2 (en) 2014-07-31
TWI555751B (en) 2016-11-01
AU2011215250A1 (en) 2012-09-06
RU2012138445A (en) 2014-03-20
BR112012020110B1 (en) 2021-06-08
ES2502740T3 (en) 2014-10-06
SG183243A1 (en) 2012-09-27
EP2535342A1 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
FR22C1049I1 (en) CONDENSED HETEROCYCLIC DERIVATIVE SALT AND CRYSTALS THEREOF
CY2021001I2 (en) HETEROCYCLIC AMIDE DERIVATIVES USEFUL AS MICROBIOTICIDES
HUE028396T2 (en) Condensed heterocyclic compounds and their use for pest control
LTC2447254I2 (en) CRYSTALS
EP2782570A4 (en) HETEROCYCLIC GLUTAMINASE INHIBITORS
DK2880447T3 (en) Markers associated with sensitivity to human double minute 2 inhibitors (MDM2)
BR112013019509A2 (en) heterocyclic derivatives
EP2863918A4 (en) SALT CRYSTALS
HUE036582T2 (en) Nitrogen-containing heterocyclic compound or salt thereof
EP2920168A4 (en) HETEROCYCLIC GLUTAMINASE INHIBITORS
HRP20150878T1 (en) CONDENSED HETEROAROMATIC PYROLIDINONES AS SYK INHIBITORS
EP2759533A4 (en) CONDENSED HETEROCYCLIC COMPOUND
DK2540728T3 (en) Heterocyclic compound
EP2857396A4 (en) CONDENSED HETEROCYCLIC COMPOUND
SG11201503042QA (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
EP2857397A4 (en) CONDENSED HETEROCYCLIC COMPOUND
PL2593452T3 (en) Heterocyclic compounds that are agonists of the IP receptor
BR112013014943A2 (en) compounds useful for the treatment of AIDS
DK3777876T3 (en) N-acyl dipeptide derivatives and uses thereof
PL2658851T3 (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
DK3392252T3 (en) PYRIMIDO-PYRIDAZINONE COMPOUNDS AND THEIR USE
BR112013010643A2 (en) heterocyclic compounds
SI3246325T1 (en) Crystals of 2-acylaminothiazole compounds
HUE037584T2 (en) Nitrogen-containing saturated heterocyclic compound
ME02733B (en) BICYCLIC HETEROCYCLIC UNIT